Hematopoietic Stem Cell Transplants in Europe: data and trends in 2011 (includes CLL)
HSCT continues to increase for some indications but not for others. Of interest is an important growth of allogeneic HSCT for myelodysplastic syndrome, CLL and for non-malignant disorders, in particular marrow failure and inherited disorders of metabolism.
Last edited by AussieNeil
